VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research note on Wednesday, March 12th. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Down 2.3 %

Shares of VNRX opened at $0.54 on Thursday. The firm’s 50-day moving average price is $0.60 and its 200-day moving average price is $0.64. The firm has a market capitalization of $50.44 million, a price-to-earnings ratio of -1.51 and a beta of 1.09. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.02.

Institutional Investors Weigh In On VolitionRx

Several hedge funds have recently bought and sold shares of VNRX. Geode Capital Management LLC boosted its stake in VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares in the last quarter. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the fourth quarter worth approximately $29,000. Northern Trust Corp lifted its stake in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Lagoda Investment Management L.P. lifted its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of VolitionRx in the fourth quarter worth approximately $36,000. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.